WO2013153155A3 - Utilisation de particules de miarn et d'antagomir de miarn pour le diagnostic, la prévention et le traitement de la sclérose en plaques - Google Patents

Utilisation de particules de miarn et d'antagomir de miarn pour le diagnostic, la prévention et le traitement de la sclérose en plaques Download PDF

Info

Publication number
WO2013153155A3
WO2013153155A3 PCT/EP2013/057585 EP2013057585W WO2013153155A3 WO 2013153155 A3 WO2013153155 A3 WO 2013153155A3 EP 2013057585 W EP2013057585 W EP 2013057585W WO 2013153155 A3 WO2013153155 A3 WO 2013153155A3
Authority
WO
WIPO (PCT)
Prior art keywords
mirna
prevention
treatment
multiple sclerosis
diagnostics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2013/057585
Other languages
English (en)
Other versions
WO2013153155A2 (fr
Inventor
Marcin MYCKO
Krzysztof Selmaj
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2013153155A2 publication Critical patent/WO2013153155A2/fr
Publication of WO2013153155A3 publication Critical patent/WO2013153155A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne l'utilisation de particules d'ARN non codant (microARN) et d'antagomirs de microARN en médecine, en particulier pour la prévention et le traitement de maladies auto-immunes, notamment pour la sclérose en plaques.
PCT/EP2013/057585 2012-04-11 2013-04-11 Utilisation de particules de miarn et d'antagomir de miarn pour le diagnostic, la prévention et le traitement de la sclérose en plaques Ceased WO2013153155A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL398796A PL398796A1 (pl) 2012-04-11 2012-04-11 Zastosowanie czasteczek miRNA oraz antagomiru dla miRNA w diagnostyce, zapobieganiu i leczeniu stwardnienia rozsianego
PLP398796 2012-04-11

Publications (2)

Publication Number Publication Date
WO2013153155A2 WO2013153155A2 (fr) 2013-10-17
WO2013153155A3 true WO2013153155A3 (fr) 2013-12-05

Family

ID=48669859

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/057585 Ceased WO2013153155A2 (fr) 2012-04-11 2013-04-11 Utilisation de particules de miarn et d'antagomir de miarn pour le diagnostic, la prévention et le traitement de la sclérose en plaques

Country Status (2)

Country Link
PL (1) PL398796A1 (fr)
WO (1) WO2013153155A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111777667B (zh) * 2020-07-10 2022-09-09 上海交通大学医学院 小肽及其在制备免疫调节药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011003989A1 (fr) * 2009-07-08 2011-01-13 Administración General De La Comunidad Autónoma De Euskadi Méthodes de diagnostic de la sclérose en plaques se basant sur le profilage de l'expression de ses microarn
WO2012037043A2 (fr) * 2010-09-13 2012-03-22 California Institute Of Technolgoy Traitement d'une inflammation auto-immune en utilisant le mir-155
WO2013013165A2 (fr) * 2011-07-21 2013-01-24 The Trustees Of The University Of Pennsylvania Utilisation de composés d'acide nucléique bloqué (lna) pour l'inhibition thérapeutique de mir-21 dans le lupus érythémateux systémique

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011003989A1 (fr) * 2009-07-08 2011-01-13 Administración General De La Comunidad Autónoma De Euskadi Méthodes de diagnostic de la sclérose en plaques se basant sur le profilage de l'expression de ses microarn
WO2012037043A2 (fr) * 2010-09-13 2012-03-22 California Institute Of Technolgoy Traitement d'une inflammation auto-immune en utilisant le mir-155
WO2013013165A2 (fr) * 2011-07-21 2013-01-24 The Trustees Of The University Of Pennsylvania Utilisation de composés d'acide nucléique bloqué (lna) pour l'inhibition thérapeutique de mir-21 dans le lupus érythémateux systémique

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHANGSHENG DU ET AL: "MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis", NATURE IMMUNOLOGY, vol. 10, no. 12, 18 October 2009 (2009-10-18), pages 1252 - 1259, XP055081713, ISSN: 1529-2908, DOI: 10.1038/ni.1798 *
G. MURUGAIYAN ET AL: "Silencing MicroRNA-155 Ameliorates Experimental Autoimmune Encephalomyelitis", THE JOURNAL OF IMMUNOLOGY, vol. 187, no. 5, 25 July 2011 (2011-07-25), pages 2213 - 2221, XP055082209, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1003952 *
JUNKER ANDREAS ET AL: "MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47", BRAIN, OXFORD UNIVERSITY PRESS, OXFORD, GB, vol. 132, no. 12, 1 December 2009 (2009-12-01), pages 3342 - 3352, XP008125500, ISSN: 0006-8950, [retrieved on 20091201], DOI: 10.1093/BRAIN/AWP300 *
M. P. MYCKO ET AL: "PNAS Plus: microRNA-301a regulation of a T-helper 17 immune response controls autoimmune demyelination", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 109, no. 20, 15 May 2012 (2012-05-15), pages E1248 - E1257, XP055081763, ISSN: 0027-8424, DOI: 10.1073/pnas.1114325109 *
MYCKO MARCIN P ET AL: "MicroRNA301a Downregulation Attenuates Animal Model of MS", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, vol. 76, no. 9, Supplemet 4, 1 March 2011 (2011-03-01), pages A652, XP008165096, ISSN: 0028-3878 *
RYAN M. O'CONNELL ET AL: "MicroRNA-155 Promotes Autoimmune Inflammation by Enhancing Inflammatory T Cell Development", IMMUNITY, vol. 33, no. 4, 30 September 2010 (2010-09-30), pages 607 - 619, XP055081715, ISSN: 1074-7613, DOI: 10.1016/j.immuni.2010.09.009 *

Also Published As

Publication number Publication date
PL398796A1 (pl) 2013-10-14
WO2013153155A2 (fr) 2013-10-17

Similar Documents

Publication Publication Date Title
IL278396A (en) Neuroactive steroids converted at the 19th position to the 17th position, their prodrugs, and methods of treatment using them
WO2013018060A3 (fr) Micro-arn et compositions les comprenant pour le traitement et le diagnostic de troubles médicaux associés à la sérotonine, à l'adrénaline, à la noradrénaline, au glutamate et à l'hormone de libération de la corticotropine
WO2014036219A3 (fr) Procédés et compositions de traitement d'un état génétique
IL262493A (en) Methylphenidate - drugs that process and prepare them
PH12012502452A1 (en) Vectors and sequences for the treatment of diseases
WO2014007620A3 (fr) Oligonucléotide pour le traitement de patients atteints de dystrophie musculaire
WO2012125987A3 (fr) Système d'administration
WO2014028429A3 (fr) Enzymes et polymérases destinées à la synthèse d'arn
EP4279610A3 (fr) Purification d'acide ribonucléique
WO2013016352A8 (fr) Produits viraux recombinants et procédés pour inhibition de l'expression de dux4
PL2820051T3 (pl) Pochodne na bazie kwasu hialuronowego, zdolne do tworzenia hydrożeli, sposób ich wytwarzania, hydrożele na bazie tych pochodnych, sposób ich wytwarzania i zastosowanie
PL2882779T3 (pl) Pochodna kwasu hialuronowego, sposób jej wytwarzania, sposób jej modyfikacji i jej zastosowanie
LT2974732T (lt) Natūralaus indigo alyva ekstrahuotas produktas ir jo gavimo būdas ir panaudojimas
WO2015048020A3 (fr) Compositions et procédés de fabrication de nanoparticules lipidiques
AP2014007804A0 (en) Compositions and methods for the treatment of hepatic diseases and disorders.
WO2014015210A3 (fr) Micro-organismes et procédés de conversion de glycérol en isoprène
EP3104862A4 (fr) Conception, synthèse et activité biologique d'agents hybrides au platine-benz [c]acridine et procédés associés à ces derniers
SG10201703677VA (en) Methods of treating s. aureus-associated diseases
WO2015012541A3 (fr) Kit de diagnostic précoce de la maladie d'alzheimer
WO2013023059A3 (fr) Méthodes et compositions pour le traitement de maladies auto-immunes et inflammatoires
TN2014000327A1 (en) Oligonucleotides for modulating gene expression and uses thereof
WO2011130426A3 (fr) Compositions et procédés de traitement de mélanome
WO2013072933A3 (fr) Procédé de préparation de 2-acétamido-n-benzyl-3-méthoxypropionamide
WO2015007871A3 (fr) Micro-arn et maladie inflammatoire à médiation auto-immune
WO2014031881A3 (fr) Paires de gènes activité-dépendants à titre de cibles thérapeutiques et méthodes et dispositifs permettant de les identifier

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 13730123

Country of ref document: EP

Kind code of ref document: A2